← Back to headlines
Sanofi Unveils Phase 3 Amlitelimab Data for Atopic Dermatitis
Sanofi has announced late-breaking phase 3 data for its drug amlitelimab, targeting atopic dermatitis, a significant development in the treatment of the skin condition.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
